Toll-like Receptor 5 Agonist Inhibition of Growth of A549 Lung Cancer Cells in Vivo in a Myd88 Dependent Manner

  • Zhou, Shi-Xiang (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine) ;
  • Li, Feng-Sheng (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine) ;
  • Qiao, Yu-Lei (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine) ;
  • Zhang, Xue-Qing (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine) ;
  • Wang, Zhi-Dong (Department of Radiation Toxicology and Oncology, Beijing Institute of Radiation Medicine)
  • Published : 2012.06.30


The purpose of this study was to examine the effect of a Toll-like receptor 5 (TLR5) agonist, CBLB502, on the growth and radiosensitivity of A549 lung cancer cells in vivo. Expression of myeloid differentiation factor 88 (MyD88) or TLR5 was stably knocked down in human lung cancer cells (A549) using lentivirus expressing short hairpin RNA targeting human MyD88 or TLR5. Lack of MyD88 or TLR5 expression enhanced tumor growth in mouse xenografts of A549 lung cancer cells. CBLB502 inhibited the growth of A549 lung cancer cells, not A549-MyD88-KD cells in vivo in the murine xenograft model. Our results showed that the inhibition of A549 by CBLB502 in vivo was realized through regulating the expression of neutrophil recruiting cytokines and neutrophil infiltration. Finally, we found that activation of TLR5 signaling did not affect the radiosensitivity of tumors in vivo.


Supported by : Beijing Natural Science Foundation


  1. Armant MA, Fenton MJ (2002). Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol, 3, REVIEWS3011.
  2. Bickels J, Kollender Y, Merinsky O, Meller I (2002). Coley's toxin: historical perspective. Isr Med Assoc J, 4, 471-2.
  3. Burdelya LG, Krivokrysenko VI, Tallant TC, et al (2008). An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320, 226-30
  4. Challacombe JM, Suhrbier A, Parsons PG, et al (2006). Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol, 177, 8123-32.
  5. Cheng YS, Xu F (2011). Anticancer function of polyinosinicpolycytidylic acid. Cancer Biol Ther, 10, 1219-23.
  6. Di CE, Forni G, Lollini P, et al (2001). The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood, 97, 339-45.
  7. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL (2001). Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol, 167, 1882-5.
  8. Hartman ZC, Osada T, Glass O, et al (2010). Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res, 70, 7209-20.
  9. Hicks AM, Riedlinger G, Willingham MC, et al (2006). Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA, 103, 7753-8.
  10. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007). Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med, 13, 552-9.
  11. Kawai T, Akira S (2006). TLR signaling. Cell Death Differ, 13, 816-25.
  12. Kawai T, Akira S (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 11, 373-84.
  13. Khoo JJ, Forster S, Mansell A (2011). Toll-like receptors as interferon-regulated genes and their role in disease. J Interferon Cytokine Res, 31, 13-25.
  14. Lin YS, Huang LD, Lin CH, et al (2011). In vitro and in vivo anticancer activity of a synthetic glycolipid as TLR4 activator. J Biol Chem, (in press).
  15. Narayanan P, Lapteva N, Seethammagari M, et al (2011). A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest, 121, 1524-34.
  16. Nozawa H, Chiu C, Hanahan D (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA, 103, 12493-8.
  17. Ostberg JR, Ertel BR, Lanphere JA (2005). An important role for granulocytes in the thermal regulation of colon tumor growth. Immunol Invest, 34, 259-72.
  18. Rhee SH, Im E, Pothoulakis C (2008). Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology, 135, 518-28.
  19. Rhee SH, Im E, Riegler M, et al (2005). Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci USA, 102, 13610-5.
  20. Rhee SH, Kim H, Moyer MP, Pothoulakis C (2006). Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells. J Biol Chem, 281, 18560-8.
  21. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006). TLR3 can directly trigger apoptosis in human cancer cells. J Immunol, 176, 4894-901.
  22. Thomas JA, Badini M (2011). The role of innate immunity in spontaneous regression of cancer. Indian J Cancer, 48, 246-51.
  23. Tse BW, Russell PJ, Lochner M, Forster I, Power CA (2011). IL- 18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS ONE, 6, e24241.
  24. Wolska A, Lech-Maranda E, Robak T (2009). Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett, 14, 248-72.
  25. Xie Q, Gan L, Wang J, Wilson I, Li L (2007). Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol, 44, 3453-61.
  26. Zhang Y, Luo F, Cai Y, et al (2011). TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol, 186, 1963-9.
  27. Zhang Y, Sun R, Liu B, et al (2009). TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4. Cancer Biol Ther, 8, 1826-30.

Cited by

  1. Toll-like Receptor 5 Agonism Protects Mice from Radiation Pneumonitis and Pulmonary Fibrosis vol.13, pp.9, 2012,
  2. Utilizing bacterial flagellins against infectious diseases and cancers vol.105, pp.2, 2014,
  3. Strahlenschutz von Normalgewebszellen vol.190, pp.8, 2014,
  4. Role of toll-like receptors in lung cancer vol.34, pp.5, 2014,
  5. Damage-Associated Molecular Patterns in the Course of Lung Cancer - A Review vol.82, pp.2, 2015,
  6. Anti-tumor Activity of Toll-Like Receptor 7 Agonists vol.8, pp.1663-9812, 2017,
  7. Repeated injection of KMRC011, a medical countermeasure for radiation, can cause adverse health effects in cynomolgus monkeys pp.0260437X, 2018,